Drug intelligence / Profile preview

Cefaliv

Development stage: Preclinical
Lead developer: Ache Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

**Cefaliv** is an oral fixed-dose antimigraine tablet marketed by Aché for acute headache attacks, including migraine. Each tablet contains dihydroergotamine mesylate 1 mg, dipyrone monohydrate 350 mg, and caffeine 100 mg. Dihydroergotamine is an ergot-derived antimigraine agent with agonist activity at serotonin 5-HT1B and 5-HT1D receptors; dipyrone provides non-opioid analgesic and antipyretic activity; and caffeine is an analgesic adjuvant that antagonizes adenosine receptors. ([bula.ache.com.br](https://bula.ache.com.br/produto/sob-prescricao/cefaliv?sitejourney=true))

Brand names: Cefaliv
Other names: caffeine + dihydroergotamine mesylate + dipyrone monohydrate

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DRD4 (Dopamine D4 Receptor)ADRA2C (α2C)ADRA1A (α1A)HTR2A (Serotonin receptor 5-HT2A)ADORA1 (Adenosine receptor A1 subtype)HTR1F (Serotonin 5-HT1F receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR3A (5-hydroxytryptamine receptor 3A)HTR1D (5-hydroxytryptamine receptor 1D)ADRA2A (α2A)HTR2C (5-hydroxytryptamine 2C receptor)ADRA1B (α1B)ADRA2B (α2B)DRD3 (Dopamine receptor D3)HTR1B (5-Hydroxytryptamine Receptor 1B)DRD2 (Dopamine D2 Receptor)ADORA2A (Adenosine A₂A Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Cefaliv.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cefaliv.

Explore the full profile